Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

VJHemOnc was pleased to be a media partner for the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023), which was held on 6-9 September, 2023, in Houston, TX, and online. This meeting brought world leaders in the field of hematological oncology together to discuss the latest advances and practical clinical applications in hematologic malignancies.
View all videos

SOHO 2023

The 11th Annual Meeting of the Society of Hematologic Oncology
06–09 September 2023 | Houston, TX / Online
Retweet on Twitter VJHemOnc Retweeted
jjkiladjian avatar; J.J. Kiladjian @jjkiladjian ·
10 Dec 1733663947260334511

#ASH23 a great opportunity to discuss with colleagues from #Armenia about the development of clinical research in hematology in Yerevan @NersesGH Prof. Y. Hakobyan #ArmenianHematologyAssociation

Image for the Tweet beginning: #ASH23 a great opportunity to Twitter feed image.
Reply on Twitter 1733663947260334511 Retweet on Twitter 1733663947260334511 4 Like on Twitter 1733663947260334511 18 View Tweet 1733663947260334511
Retweet on Twitter VJHemOnc Retweeted
RahulBanerjeeMD avatar; Rahul Banerjee, MD, FACP @RahulBanerjeeMD ·
10 Dec 1733660012046856430

#ASH23 HOVON analysis of dynamic frailty in #MMsm - building on work by @HiraSMian @tanyawildes et al.

Some pts get less frail with myeloma treatment đź‘Ź

Also note that, of pts who become “frailer,” some of this is artifactual because IMWG model de facto penalizes older age.

Image for the Tweet beginning: #ASH23 HOVON analysis of dynamic Twitter feed image.
Image for the Tweet beginning: #ASH23 HOVON analysis of dynamic Twitter feed image.
Reply on Twitter 1733660012046856430 Retweet on Twitter 1733660012046856430 1 Like on Twitter 1733660012046856430 6 View Tweet 1733660012046856430
VJHemOnc avatar; VJHemOnc @VJHemOnc ·
10 Dec 1733658332047856117

Great chatting with @tarekmd91 (@IcahnMountSinai) who gave an overview of updates on the use of #CART in #MultipleMyeloma

@ASH_hematology #Myeloma #MMsm #HemOnc

Image for the Tweet beginning: Great chatting with @tarekmd91 (@IcahnMountSinai) Twitter feed image.
Reply on Twitter 1733658332047856117 Retweet on Twitter 1733658332047856117 1 Like on Twitter 1733658332047856117 8 View Tweet 1733658332047856117
VJHemOnc avatar; VJHemOnc @VJHemOnc ·
10 Dec 1733649005551517749

#ASH23 | We spoke with @NersesGH from Yeolyan Hematology and Oncology Center on challenges that remain in the diagnosis and treatment of #BPDCN

@ASH_hematology #HemOnc

Image for the Tweet beginning: #ASH23 | We spoke with Twitter feed image.
Reply on Twitter 1733649005551517749 Retweet on Twitter 1733649005551517749 4 Like on Twitter 1733649005551517749 9 View Tweet 1733649005551517749
Load More...

SOHO 2023

The 11th Annual Meeting of the Society of Hematologic Oncology
06–09 September 2023 | Houston, TX / Online
VJHemOnc was pleased to be a media partner for the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023), which was held on 6-9 September, 2023, in Houston, TX, and online. This meeting brought world leaders in the field of hematological oncology together to discuss the latest advances and practical clinical applications in hematologic malignancies.
View all videos
Retweet on Twitter VJHemOnc Retweeted
jjkiladjian avatar; J.J. Kiladjian @jjkiladjian ·
10 Dec 1733663947260334511

#ASH23 a great opportunity to discuss with colleagues from #Armenia about the development of clinical research in hematology in Yerevan @NersesGH Prof. Y. Hakobyan #ArmenianHematologyAssociation

Image for the Tweet beginning: #ASH23 a great opportunity to Twitter feed image.
Reply on Twitter 1733663947260334511 Retweet on Twitter 1733663947260334511 4 Like on Twitter 1733663947260334511 18 View Tweet 1733663947260334511
Retweet on Twitter VJHemOnc Retweeted
RahulBanerjeeMD avatar; Rahul Banerjee, MD, FACP @RahulBanerjeeMD ·
10 Dec 1733660012046856430

#ASH23 HOVON analysis of dynamic frailty in #MMsm - building on work by @HiraSMian @tanyawildes et al.

Some pts get less frail with myeloma treatment đź‘Ź

Also note that, of pts who become “frailer,” some of this is artifactual because IMWG model de facto penalizes older age.

Image for the Tweet beginning: #ASH23 HOVON analysis of dynamic Twitter feed image.
Image for the Tweet beginning: #ASH23 HOVON analysis of dynamic Twitter feed image.
Reply on Twitter 1733660012046856430 Retweet on Twitter 1733660012046856430 1 Like on Twitter 1733660012046856430 6 View Tweet 1733660012046856430
VJHemOnc avatar; VJHemOnc @VJHemOnc ·
10 Dec 1733658332047856117

Great chatting with @tarekmd91 (@IcahnMountSinai) who gave an overview of updates on the use of #CART in #MultipleMyeloma

@ASH_hematology #Myeloma #MMsm #HemOnc

Image for the Tweet beginning: Great chatting with @tarekmd91 (@IcahnMountSinai) Twitter feed image.
Reply on Twitter 1733658332047856117 Retweet on Twitter 1733658332047856117 1 Like on Twitter 1733658332047856117 8 View Tweet 1733658332047856117
VJHemOnc avatar; VJHemOnc @VJHemOnc ·
10 Dec 1733649005551517749

#ASH23 | We spoke with @NersesGH from Yeolyan Hematology and Oncology Center on challenges that remain in the diagnosis and treatment of #BPDCN

@ASH_hematology #HemOnc

Image for the Tweet beginning: #ASH23 | We spoke with Twitter feed image.
Reply on Twitter 1733649005551517749 Retweet on Twitter 1733649005551517749 4 Like on Twitter 1733649005551517749 9 View Tweet 1733649005551517749
Load More...

Latest videos

View all videos
3:05
The clinical use of circulating tumor DNA in T-cell lymphomas
Jasmine Zain • 8 Sep 2023
1:18
Immunotherapeutic approaches in CALR-mutated MPNs
John Mascarenhas • 9 Sep 2023
1:33
The impact of prior therapies on the outcomes of patients with R/R ALL treated with CAR-T therapy
Bijal Shah • 8 Sep 2023
1:27
TP53-aberrant MCL: challenges and treatment approaches
Bijal Shah • 8 Sep 2023

MDS

View all
1:34
Managing adverse events with novel therapies in lower-risk MDS
Valeria Santini • 7 Sep 2023
1:02
Emerging treatment options for lower- and higher-risk MDS and ongoing trials
Guillermo Garcia-Manero • 9 Sep 2023

Lymphoma

View all
3:05
The clinical use of circulating tumor DNA in T-cell lymphomas
Jasmine Zain • 8 Sep 2023
1:27
TP53-aberrant MCL: challenges and treatment approaches
Bijal Shah • 8 Sep 2023

AML

View all
1:46
Optimizing conditioning regimens in patients with AML undergoing alloSCT
Edmund Waller • 8 Sep 2023
2:09
Improving transplantation outcomes in patients with active AML: current approaches & future outlooks
Edmund Waller • 8 Sep 2023

Multiple Myeloma

View all
3:49
The importance of correctly identifying MGUS and SMM in patients to prevent progression to myeloma
Claudio Cerchione • 6 Sep 2023
4:03
IKEMA long-term sub-group analysis: Isa-Kd for 1q21+ multiple myeloma
Thomas Martin • 11 Sep 2023
The content of VJHemOnc is intended for healthcare professionals